Goldspire™: A Biologic-Device Combination Immunotherapy that Induces Preclinical Anti-Tumor Responses Against Multiple Solid Tumors Shows Clinical Activity in Glioblastoma
Time: 9:00 am
day: Conference Day One
Details:
- Utilizing a biodiffusion chamber releasing tumor antigens and an IGF1R antisense for effective treatment of glioblastoma
- Realizing the platform configuration to maximize immunogenic cell death
- Exploring long-term survival and immunity of glioblastoma patients receiving individualized immunotherapy
